https://www.selleckchem.com/pr....oducts/Nicotinamide(
BACKGROUND The presence of chronic kidney disease (CKD) influences the type of antiglycaemic therapy and the risk for hypoglycaemia. METHODS In 2006, 2011 and 2016 health insurance data of people with diabetes type 2 were screened for CKD and the presence of severe hypoglycaemia (sHypo). The type of antihyperglycaemic therapy was recorded due to Anatomical Therapeutic Chemical (ATC) codes up to 3 months before suffering sHypo. RESULTS The prevalence of CKD increased from 5.3% in 2006 to 7.3% in 2011 and 11.2% in 2016.
Like
Comment
Share
